Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qiming Closes $120 Million US Healthcare Fund; Two General China Funds with $1.2 Billion

publication date: Apr 16, 2018

Qiming Venture Partners closed three new funds with total commitments of $1.4 billion, bringing its total assets under management to $4 billion. One of the funds, the Qiming U.S. Healthcare Fund I ($120 million), will invest in early-stage US healthcare businesses. It will be based in Seattle. The other two funds, with a total of nearly $1.3 billion, are general purpose funds: one dollar based and the other denominated in RMB. These general funds will invest in China and US companies in the internet and consumer, healthcare, information technology and cleantech sectors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital